Dr. Joseph A. Treat

• 
  www.aahs.org/healthinfo/cancerheadlines/index.php?id=15 - [Cached Version]
  Last Visited: 3/31/2009  

  However, according to a retrospective analysis conducted by Joseph Treat, MD, professor of medicine at Temple University School of Medicine and medical director of the Fox Chase-Temple University Cancer Center, even patients with advanced SCLC can tolerate and benefit from the chemotherapy drug topotecan.
  
  Topotecan, the only FDA-approved chemotherapy for recurring SCLC, works by damaging DNA. This action in turn interferes with the division of cancer cells, slowing progression of the disease.
  
  "All patients, regardless of their overall health, tolerated topotecan similarly," said Treat. "And all patients experienced similar benefits related to tumor growth, disease progression and symptom relief. Perhaps most significantly, Treat added, the drug helped the sickest patients improve their overall health and cope better with their day-to-day routines.
  
  "When our patients are in poor health, we often struggle over whether to subject them to any treatment at all and have to carefully weigh the benefit against the potential harm. This analysis identifies a new option for patients who previously had none," said Treat.

• 
  ADVANCE for Managers of Respiratory Care | Editorial - [Cached Version]
  Published on: 4/13/2004    Last Visited: 4/13/2004  

  However, according to a retrospective analysis conducted by Joseph Treat, MD, professor of medicine at Temple University School of Medicine and medical director of the Fox Chase-Temple University Cancer Center, even patients with advanced SCLC can tolerate and benefit from the chemotherapy drug topotecan.
  
  Topotecan, the only FDA-approved chemotherapy for recurring SCLC, works by damaging DNA.This action in turn interferes with the division of cancer cells, slowing progression of the disease.
  
  "All patients, regardless of their overall health, tolerated topotecan similarly," Dr. Treat said."And all patients experienced similar benefits related to tumor growth, disease progression and symptom relief."Perhaps most significantly, he added, the drug helped the sickest patients improve their overall health and cope better with their day-to-day routines.

• 
  Advanced small-cell lung cancer patients - [Cached Version]
  Published on: 3/31/2004    Last Visited: 3/31/2004  

  However, according to a retrospective analysis conducted by Joseph Treat, MD, professor of medicine at Temple University School of Medicine and medical director of the Fox Chase-Temple University Cancer Center, even patients with advanced SCLC can tolerate and benefit from the chemotherapy drug topotecan.
  
  Topotecan, the only FDA-approved chemotherapy for recurring SCLC, works by damaging DNA.This action in turn interferes with the division of cancer cells, slowing progression of the disease.
  
  "All patients, regardless of their overall health, tolerated topotecan similarly," said Treat."And all patients experienced similar benefits related to tumor growth, disease progression and symptom relief."Perhaps most significantly, Treat added, the drug helped the sickest patients improve their overall health and cope better with their day-to-day routines.
  
  "When our patients are in poor health, we often struggle over whether to subject them to any treatment at all and have to carefully weigh the benefit against the potential harm.This analysis identifies a new option for patients who previously had none," said Treat.

• 
  Advances in SCLC: Challenging Patients, Difficult... - [Cached Version]
  Published on: 1/20/2003    Last Visited: 10/28/2003  

  Joseph Treat, MDVice Chairman, Department of Medical OncologyProfessor of Medicine, Medical DirectorFox Chase-Temple Cancer Center
  ...
  Joseph Treat, MD, is a consultant for Neopharm Inc; and is on the speakers bureau of Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, and Eli Lilly and Company.

• 
  Faculty - [Cached Version]
  Published on: 4/11/2001    Last Visited: 9/6/2001  

  Joseph Treat , MDVice-Chairman and Senior MemberFox Chase Cancer CenterMedical Director and ProfessorFox Chase-Temple Cancer CenterPhiladelphia , PA

• 
  Joseph Treat, MD - [Cached Version]
  Published on: 12/2/2008    Last Visited: 12/2/2008  

  Joseph Treat, MD
  
  Medical Oncology
  
  Attending Physician
  
  Fox Chase Cancer Center 333 Cottman Avenue Philadelphia, PA 19111-2497
  ...
  Joseph Treat, MD

• 
  Joseph Treat, MD at Fox Chase Cancer Center - [Cached Version]
  Published on: 8/11/2006    Last Visited: 3/27/2008  

  Joseph Treat, MD
  
  Medical Oncology
  
  Attending Physician
  
  Joseph Treat, MD

• 
  Lung Cancer Patient Care Team - [Cached Version]
  Published on: 12/2/2008    Last Visited: 12/2/2008  

  Joseph Treat, MD

• 
  Memorial Health - CME Programs - [Cached Version]
  Published on: 6/9/2004    Last Visited: 2/22/2005  

  Joseph Treat, M.D., associate medical director of the Fox Chase-Temple Cancer Center in Philadelphia, will give a breakfast lecture entitled, "Clinical Discussion of the 2nd Line Treatment of NSCLC."

• 
  News - [Cached Version]
  Published on: 4/5/2002    Last Visited: 11/14/2008  

  Joseph A. Treat, M.D., director of medical oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia.

Page:  1 2 3